Guided Therapeutics (GTHP) EBT Margin (2010 - 2025)

Guided Therapeutics has disclosed EBT Margin across 16 years of filings, most recently posting 206.44% for Q4 2025.

• EBT Margin for Q4 2025 came in at 206.44%, up 6499356.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 416.95% (up 3411162.0% YoY), and the FY2025 annual result was 416.69%, up 3411188.0% from the prior year.
• EBT Margin came in at 206.44% for Q4 2025 at Guided Therapeutics, up from 1236.67% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 357.89% in Q3 2021 to a low of 65200.0% in Q4 2024.
• The 5-year median for EBT Margin is 3744.32% (2023), against an average of 14300.47%.
• Across the five-year window, EBT Margin slumped 6399375 bps in 2024 and soared 6499356 bps in 2025, its largest moves.
• Guided Therapeutics' EBT Margin stood at 740.0% in 2021, then slumped by 4864 bps to 36733.33% in 2022, then soared by 97 bps to 1206.25% in 2023, then tumbled by 5305 bps to 65200.0% in 2024, then jumped by 100 bps to 206.44% in 2025.
• The last three EBT Margin figures came in at 206.44% (Q4 2025), 1236.67% (Q3 2025), and 693.16% (Q2 2025), per Business Quant data.